Metabolism of borono-phenylalanine-fructose complex (BPA-fr) and borocaptate sodium (BSH) in cancer patients--results from EORTC trial 11001.
Within the clinical trial EORTC 11001, patients were infused with (10)B-enriched borono-phenylalanine-fructose complex (BPA-fr), or borocaptate sodium (BSH) solutions, which are used as boron carriers for boron neutron capture therapy. Urine samples were periodically collected and analyzed by (10)B NMR spectroscopy. The results revealed time-dependent metabolic changes of the administered compounds. BPA-fr dissociated to the constituents BPA and fructose, and the borate group was partly cleaved from BPA. BSH was partly aggregated to a dimer form, BSSB. These observations were previously reported for cultured cells and animal models, and are confirmed here in human cancer patients.
Bendel
Peter
P
Department of Chemical Research Support, The Weizmann Institute of Science, Rehovot, Israel. peter.bendel@weizmann.ac.il
Wittig
Andrea
A
Basilico
Fabrizio
F
Mauri
Pier Luigi
PL
Sauerwein
Wolfgang
W
D000818:Animals; D001894:Borohydrides / Q000378:metabolism* / Q000652:urine; D001896:Boron Compounds / Q000737:chemistry / Q000378:metabolism* / Q000652:urine; D016754:Boron Neutron Capture Therapy / Q000379:methods*; D002294:Carcinoma, Squamous Cell / Q000628:therapy; D002986:Clinical Trials as Topic; D005632:Fructose / Q000737:chemistry; D006258:Head and Neck Neoplasms / Q000628:therapy; D006801:Humans; D009682:Magnetic Resonance Spectroscopy / Q000379:methods; D010649:Phenylalanine / Q000031:analogs & derivatives* / Q000737:chemistry / Q000378:metabolism / Q000652:urine; D013438:Sulfhydryl Compounds / Q000378:metabolism* / Q000652:urine; D013997:Time Factors
D001894:Borohydrides; D001896:Boron Compounds; D013438:Sulfhydryl Compounds; C014651:mercaptoundecahydrododecaborate; D005632:Fructose; D010649:Phenylalanine; C033685:4-boronophenylalanine